News & Events

Filter Year   Keywords   > Submit

Page 1 2

New Data Suggesting that ChemGenex's Omacetaxine Can Eradicate Leukemic

27 / 03 / 2009

-- New Data Published in Leukemia Showed 90% Kill of Leukemic Stem Cells and Prolonged Survival in Mice with Resistant CML - Data showing the ability of omacetaxine to kill leukemic stem cells in mouse models with drug-resistant chronic myelogenous leukemia (CML) are…

> Read More

Xenome - Addition to US patent portfolio for Xen2174

23 / 03 / 2009

Xenome Limited ("Xenome") today announced the issuance of US patent 7,507,717 entitled "Type II chi-conotoxin peptides (noradrenaline transporter inhibitors)". This patent adds to the extensive portfolio surrounding chi-conopeptides and analogues, including Xen2174, theâ?¦

> Read More

Arana - Shareholder Update - Bid from Cephalon

10 / 03 / 2009

Dear Arana Shareholder, I am writing to you to ensure you are up to date with several important developments for Arana Therapeutics Limited ("Arana"). As you may already be aware, on 27 February 2009 Cephalon, Inc. (Nasdaq: CEPH) announced that its wholly-ownedâ?¦

> Read More

Cephalon announces intention to offer $1.40 per share for Arana

27 / 02 / 2009

Cephalon, Inc. (Nasdaq: CEPH) today announced that its wholly-owned subsidary, Cephalon International Holdings, Inc., intends to make a cash takeover offer for all of the shares in Arana Therapeutics Limited which it does not already own (ASX: AAH) ("Arana") at a minimum price of $1.40 per…

> Read More

STRATEGIC RELATIONSHIP UPDATE

18 / 02 / 2009

CogState Ltd (ASX:CGS) and United BioSource Corporation (UBC) announced today that they will not renew the strategic relationship the two companies initiated in 2008 to co-market and co-deliver CogState's ClinicalTrials software for computerized cognitive testing in clinical trials. …

> Read More

Positive Results for Peplin's Phase IIb AK Trial

08 / 01 / 2009

Met primary efficacy endpoint with statistically significant complete clearance rate of AK lesions vs. vehicle Reduction in overall lesion count in all active treatment groups Well-tolerated, rapidly resolving local skin responses at all concentrations and durations …

> Read More

Xenome Grants MedImmune License to xdiscoverT Venom Peptide Library

08 / 01 / 2009

Xenome Limited ("Xenome") today announced it has executed a research licence agreement with MedImmune LLC (MedImmune"), a wholly owned subsidiary of AstraZeneca. Under the partnership MedImmune will gain access to Xenome's xdiscoverT venom peptide library to exclusively…

> Read More

The Plantronics Discovery 925 Wins 7B Labs'' Premium Bluetooth

07 / 01 / 2009

Plantronics Discovery 925 beats competitors from Jawbone, BlueAnt and Motorola in an independent consumer research study performed by 7B Labs. 7B Labs announced today that the Plantronics Discovery 925 has won its Premium Bluetooth Headset Challenge, beating out the Aliph…

> Read More

NUON THERAPEUTICS INC. NAMES MICHAEL M. KITT, M.D.,

05 / 01 / 2009

Nuon Therapeutics, Inc., a clinical stage biotechnology company focused on novel therapies for autoimmune and chronic inflammatory diseases and pain, today announced the appointment of Michael M. Kitt, M.D., to the position of Chief Medical Officer. "Dr. Kitt is an…

> Read More

 
Displaying records 51-59 of 59